Whole Cell (wP) Hexavalent vaccine and feasibility OR “successful implementation” OR “financial barriers” OR “vaccine supply” OR “vaccine use”
Balasubramanian, S., Shah, A., Pemde, H. K., Chatterjee, P., Shivananda, S., Guduru, V. K., Soans, S., Shastri, D., & Kumar, R. (2018). Indian academy of pediatrics (IAP) advisory committee on vaccines and immunization practices (ACVIP) recommended immunization schedule (2018-19) and update on immunization for children aged 0 through 18 years. Indian Pediatrics, 55, 1066–1074. (NOT OA)
Batson, A., Federgruen, A., Ganguly, N. K., Glassman, A., Makoni, S., & Plotkin, S. (2021). Polio eradication vaccine investment: How do we ensure polio vaccines are available to keep the world polio-free after transmission of wild poliovirus (wPV) has been interrupted? BMJ Global Health, 6(11), e006447. doi:10.1136/ bmjgh-2021-006447
Kana, B. D., Arbuthnot, P., Botwe, B. K., Choonara, Y. E., Hassan, F., Louzir, H., Matsoso, P., Moore, P. L., Muhairwe, A., & Naidoo, K. (2023). Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa. The Lancet Infectious Diseases, 23(8), e288–e300. https://doi.org/10.1016/ S1473-3099(22)00878-7
Kumar, P., Hamana, A., Bird, C., Dotson, B., Saleh-Birdjandi, S., Volkin, D. B., & Joshi, S. B. (2024). Evaluating the Compatibility of Three Aluminum Salt-Adjuvanted Recombinant Protein Antigens (Trivalent NRRV) Combined with a Mock Trivalent Sabin-IPV Vaccine: Analytical and Formulation Challenges. Vaccines, 12(10), 1102. ttps://doi.org/10.3390/vaccines12101102
Lecrenier, N., Marijam, A., Olbrecht, J., Soumahoro, L., Nieto Guevara, J., & Mungall, B. (2020). Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children. Expert Review of Vaccines, 19(3), 247–265. https://doi.org/10.1080/14760584.2020.1738226
Lopez Cavestany, R., Eisenhawer, M., Diop, O. M., Verma, H., Quddus, A., & Mach, O. (2024). The last mile in polio eradication: Program challenges and perseverance. Pathogens, 13(4), 323. https://doi.org/10.3390/pathogens13040323
Shah, A. K., & Shah, A. A. (2020). POLIO VACCINES. Indian Journal of Practical Pediatrics, 22(4), 370. https://drabhaykshah.in/wp-content/uploads/2022/07/IJPP-POLIO-VACCINES.pdf
Sharma, H., Parekh, S., Pujari, P., Shewale, S., Desai, S., Kawade, A., Lalwani, S., Ravi, M. D., Kamath, V., & Mahopatra, J. (2024). A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants. Npj Vaccines, 9(1), 41. https://doi.org/10.1038/s41541-024-00828-w